Expert Discusses the Role of PD-L1 Expression as a Predictive Biomarker in Urothelial Carcinoma
Robert Dreicer, MD, discusses the role of biomarkers to predict response to immunotherapy in patients with urothelial carcinoma. He highlights the current status of using PD-L1 expression as a predictive biomarker to immunotherapy.
Robert Dreicer, MD, associate director for clinical research and the deputy director of the University of Virginia Cancer Center, discusses the role of biomarkers to predict response to immunotherapy in patients with urothelial carcinoma. He highlights the current status of using PD-L1 expression as a predictive biomarker to immunotherapy.
PD-L1 expression is not necessarily useful in deciding which patients with urothelial carcinoma will respond to checkpoint inhibition because patients that don’t express PD-L1 can still respond to this type of therapy, Dreicer says. However,an FDA guidance says that PD-L1 expression may be useful when treating patientsin the frontline with single-agent checkpoint inhibitors and that patients who are platinum eligible and have low PD-L1 expression should not receive immune checkpoint inhibitor monotherapy.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
